Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter real-world analysis of first-line systemic monotherapy for locally advanced basal cell carcinoma.
Groover MK, Gupta N, Granger E, Murad F, Forrester VJ, Anstadt EJ, Su W, Heusinkveld L, Lukens JN, Silk AW, Vidimos AT, Schoenfeld JD, Koyfman SA, Ruiz ES. Groover MK, et al. Among authors: silk aw. JAAD Case Rep. 2023 Oct 29;42:69-71. doi: 10.1016/j.jdcr.2023.10.006. eCollection 2023 Dec. JAAD Case Rep. 2023. PMID: 38156099 Free PMC article. No abstract available.
A multicenter real-world analysis of risk factors, therapeutics, and outcomes of patients with metastatic basal cell carcinoma.
Groover M, Gupta N, Granger E, Forrester VJ, Anstadt EJ, Su W, Heusinkveld L, Chen A, Lukens JN, Silk AW, Vidimos AT, Schoenfeld JD, Koyfman SA, Ruiz ES. Groover M, et al. Among authors: silk aw. J Am Acad Dermatol. 2024 Mar;90(3):545-551. doi: 10.1016/j.jaad.2023.10.060. Epub 2023 Nov 8. J Am Acad Dermatol. 2024. PMID: 37949119
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition.
Buchbinder EI, Dutcher JP, Daniels GA, Curti BD, Patel SP, Holtan SG, Miletello GP, Fishman MN, Gonzalez R, Clark JI, Richart JM, Lao CD, Tykodi SS, Silk AW, McDermott DF. Buchbinder EI, et al. Among authors: silk aw. J Immunother Cancer. 2019 Feb 18;7(1):49. doi: 10.1186/s40425-019-0522-3. J Immunother Cancer. 2019. PMID: 30777131 Free PMC article.
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
Stein MN, Malhotra J, Tarapore RS, Malhotra U, Silk AW, Chan N, Rodriguez L, Aisner J, Aiken RD, Mayer T, Haffty BG, Newman JH, Aspromonte SM, Bommareddy PK, Estupinian R, Chesson CB, Sadimin ET, Li S, Medina DJ, Saunders T, Frankel M, Kareddula A, Damare S, Wesolowsky E, Gabel C, El-Deiry WS, Prabhu VV, Allen JE, Stogniew M, Oster W, Bertino JR, Libutti SK, Mehnert JM, Zloza A. Stein MN, et al. Among authors: silk aw. J Immunother Cancer. 2019 May 22;7(1):136. doi: 10.1186/s40425-019-0599-8. J Immunother Cancer. 2019. PMID: 31118108 Free PMC article. Clinical Trial.
76 results